TY - JOUR
KW - Humans
KW - Female
KW - Male
KW - United Kingdom/epidemiology
KW - Incidence
KW - Aged
KW - Middle Aged
KW - *Cardiovascular Diseases/epidemiology
KW - Adult
KW - Aged, 80 and over
KW - social class
KW - Age Distribution
KW - Sex Distribution
KW - Young Adult
AU - N. Conrad
AU - G. Molenberghs
AU - G. Verbeke
AU - F. Zaccardi
AU - C. Lawson
AU - J. Friday
AU - H. Su
AU - P. Jhund
AU - N. Sattar
AU - K. Rahimi
AU - J. Cleland
AU - K. Khunti
AU - W. Budts
AU - J. McMurray
AD - School of Cardiovascular and Metabolic Health, British Heart Foundation Cardiovascular Research Centre, University of Glasgow, Glasgow, UK nathalie.conrad@kuleuven.be.
Department of Cardiovascular Sciences, KU Leuven, Leuven, Belgium.
Deep Medicine, Nuffield Department of Women's and Reproductive Health, University of Oxford, Oxford, UK.
Interuniversity Institute for Biostatistics and statistical Bioinformatics (I-BioStat), Hasselt University and KU Leuven, Belgium.
Leicester Real World Evidence Unit, Diabetes Research Centre, University of Leicester, Leicester, UK.
School of Cardiovascular and Metabolic Health, British Heart Foundation Cardiovascular Research Centre, University of Glasgow, Glasgow, UK.
College of Medical, Veterinary and Life Sciences, University of Glasgow, Glasgow, UK.
Congenital and Structural Cardiology, University Hospitals Leuven, Belgium.
AN - 38925788
BT - Bmj
C2 - PMC11203392 at www.icmje.org/disclosure-of-interest/ and declare: NC is funded by a personal fellowship from the Research Foundation Flanders and a research grant from the European Society of Cardiology. JMF, PSJ, JGC, NS, and JJVM are supported by British Heart Foundation Centre of Research Excellence. PSJ and JJVM are further supported by the Vera Melrose Heart Failure Research Fund. JJVM has received funding to his institution from Amgen and Cytokinetics for his participation in the steering sommittee for the ATOMIC-HF, COSMIC-HF, and GALACTIC-HF trials and meetings and other activities related to these trials; has received payments through Glasgow University from work on clinical trials, consulting, and other activities from Alnylam, Amgen, AstraZeneca, Bayer, Boehringer Ingelheim, Bristol Myers Squibb, Cardurion, Dal-Cor, GlaxoSmithKline, Ionis, KBP Biosciences, Novartis, Pfizer, and Theracos; and has received personal lecture fees from the Corpus, Abbott, Hikma, Sun Pharmaceuticals, Medscape/Heart.Org, Radcliffe Cardiology, Alkem Metabolics, Eris Lifesciences, Lupin, ProAdWise Communications, Servier Director, and Global Clinical Trial Partners. NS declares consulting fees or speaker honorariums, or both, from Abbott Laboratories, Afimmune, Amgen, AstraZeneca, Boehringer Ingelheim, Lilly, Hanmi Pharmaceuticals, Janssen, Merck Sharp & Dohme, Novartis, Novo Nordisk, Pfizer, Roche Diagnostics, and Sanofi; and grant support paid to his university from AstraZeneca, Boehringer Ingelheim, Novartis, and Roche Diagnostics. KK has acted as a consultant or speaker or received grants for investigator initiated studies for Astra Zeneca, Bayer, Novartis, Novo Nordisk, Sanofi-Aventis, Lilly, Merck Sharp & Dohme, Boehringer Ingelheim, Oramed Pharmaceuticals, Roche, and Applied Therapeutics. KK is supported by the National Institute for Health and Care Research (NIHR) Applied Research Collaboration East Midlands (ARC EM) and the NIHR Leicester Biomedical Research Centre (BRC). CL is funded by an NIHR Advanced Research Fellowship (NIHR-300111) and supported by the Leicester BRC. PSJ has received speaker fees from AstraZeneca, Novartis, Alkem Metabolics, ProAdWise Communications, Sun Pharmaceuticals, and Intas Pharmaceuticals; has received advisory board fees from AstraZeneca, Boehringer Ingelheim, and Novartis; has received research funding from AstraZeneca, Boehringer Ingelheim, Analog Devices; his employer, the University of Glasgow, has been remunerated for clinical trial work from AstraZeneca, Bayer, Novartis, and Novo Nordisk; and is the Director of Global Clinical Trial Partners. HS is supported by the China Scholarship Council. Other authors report no support from any organisation for the submitted work, no financial relationships with any organisations that might have an interest in the submitted work in the previous three years, and no other relationships or activities that could appear to have influenced the submitted work.
DO - 10.1136/bmj-2023-078523
DP - NLM
ET - 2024/06/27
LA - eng
N1 - 1756-1833
Conrad, Nathalie
Orcid: 0000-0001-5027-5481
Molenberghs, Geert
Verbeke, Geert
Zaccardi, Francesco
Lawson, Claire
Friday, Jocelyn M
Su, Huimin
Jhund, Pardeep S
Sattar, Naveed
Rahimi, Kazem
Cleland, John G
Khunti, Kamlesh
Budts, Werner
McMurray, John J V
Journal Article
England
BMJ. 2024 Jun 26;385:e078523. doi: 10.1136/bmj-2023-078523.
PY - 2024
SN - 0959-8138 (Print)
0959-8138
EP - e078523
T2 - Bmj
TI - Trends in cardiovascular disease incidence among 22 million people in the UK over 20 years: population based study
VL - 385
ER -